Cargando…
Motolimod effectively drives immune activation in advanced cancer patients
A novel approach to immunotherapy is the activation of toll-like receptor 8 (TLR8). Motolimod, a selective TLR8 agonist can act in concert with approved immunotherapies to sensitize T cells and augment natural killer (NK) cell function. Despite treatment with chemotherapeutic agents and advance dise...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910739/ https://www.ncbi.nlm.nih.gov/pubmed/27467937 http://dx.doi.org/10.1080/2162402X.2015.1126037 |
| _version_ | 1782438048489799680 |
|---|---|
| author | Dietsch, Gregory N. |
| author_facet | Dietsch, Gregory N. |
| author_sort | Dietsch, Gregory N. |
| collection | PubMed |
| description | A novel approach to immunotherapy is the activation of toll-like receptor 8 (TLR8). Motolimod, a selective TLR8 agonist can act in concert with approved immunotherapies to sensitize T cells and augment natural killer (NK) cell function. Despite treatment with chemotherapeutic agents and advance disease, cancer patients remain sensitive to motolimod. |
| format | Online Article Text |
| id | pubmed-4910739 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-49107392016-06-29 Motolimod effectively drives immune activation in advanced cancer patients Dietsch, Gregory N. Oncoimmunology Author's View A novel approach to immunotherapy is the activation of toll-like receptor 8 (TLR8). Motolimod, a selective TLR8 agonist can act in concert with approved immunotherapies to sensitize T cells and augment natural killer (NK) cell function. Despite treatment with chemotherapeutic agents and advance disease, cancer patients remain sensitive to motolimod. Taylor & Francis 2016-02-09 /pmc/articles/PMC4910739/ /pubmed/27467937 http://dx.doi.org/10.1080/2162402X.2015.1126037 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
| spellingShingle | Author's View Dietsch, Gregory N. Motolimod effectively drives immune activation in advanced cancer patients |
| title | Motolimod effectively drives immune activation in advanced cancer patients |
| title_full | Motolimod effectively drives immune activation in advanced cancer patients |
| title_fullStr | Motolimod effectively drives immune activation in advanced cancer patients |
| title_full_unstemmed | Motolimod effectively drives immune activation in advanced cancer patients |
| title_short | Motolimod effectively drives immune activation in advanced cancer patients |
| title_sort | motolimod effectively drives immune activation in advanced cancer patients |
| topic | Author's View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910739/ https://www.ncbi.nlm.nih.gov/pubmed/27467937 http://dx.doi.org/10.1080/2162402X.2015.1126037 |
| work_keys_str_mv | AT dietschgregoryn motolimodeffectivelydrivesimmuneactivationinadvancedcancerpatients |